Why is hybrid capture-based sequencing the optimal molecular profiling platform in precision cancer medicine? Can you use lung cancer as an example of how NGS can generate drug alignments? (Korean)

Why is hybrid capture-based sequencing the optimal molecular profiling platform in precision cancer medicine? Can you use lung cancer as an example of how NGS can generate drug alignments? (Korean)

Why is hybrid capture-based sequencing the optimal molecular profiling platform in the context of precision cancer medicine? And can you use long cancer as an example of how NGS can generate specific drug alignments?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center Yonsei University College of Medicine J JE-UK Laboratory of Molecular Cancer Therapeutics Seoul, Korea